Chemotherapy
New data illuminates research in chemotherapy
Published in Clinical Oncology Week, January 9th, 2006
Study 1: Second-line treatment with irinotecan plus cisplatin (IC) did not confer benefits over cisplatin (C) alone for non-small-cell lung cancer (NSCLC) patients.
"The aim of this study was to compare the irinotecan/cisplatin regimen with cisplatin as second-line chemotherapy in patients with advanced NSCLC pretreated with a taxane/gemcitabine regimen," scientists writing in the British Journal of Cancer reported.
"Patients (n=147) with stage IV NSCLC pretreated with a taxane/gemcitabine regimen were randomly assigned to receive...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
More Articles from Clinical Oncology Week
- Breast Cancer
Weekly administration of docetaxel and paclitaxel used to treat breast cancer - Histiocytoma
Pulmonary resection for metastatic malignant fibrous histiocytoma deemed safe - Lung Cancer
Gemcitabine and carboplatin used to treat non-small cell lung cancer - Prognostics
Prognostic factors for rhabdoid tumor of the kidney delineated - Acute Lymphoblastic Leukemia
European study confirms efficacy of clofarabine in pediatric patients with ALL - Acute Myeloid Leukemia
Acute myeloid leukemia blasts regularly express PRR1 and PRR2 - More from this issue of Clinical Oncology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
